VX3 | Merck press release filed as SEC Exhibit 99, September 30, 2004, opening paragraphs. Exact short excerpts for historical commentary:
"Merck &. Co., Inc. today announced a voluntary worldwide withdrawal of VIOXX® (rofecoxib), its arthritis and acute pain medication. The company’s decision, which is effective immediately, is based on new, three-year data from a prospective, randomized, placebo-controlled clinical trial, the APPROVe (Adenomatous Polyp Prevention on VIOXX) trial."
"In this study, there was an increased relative risk for confirmed cardiovascular events, such as heart attack and stroke, beginning after 18 months of treatment in the patients taking VIOXX compared to those taking placebo."

VX4 | Curfman, Morrissey and Drazen, NEJM Expression of Concern, online December 8, 2005 (print December 29), DOI 10.1056/NEJMe058314, p. 1. Exact short excerpt:
"Three myocardial infarctions, all in the rofecoxib group, were not included in the data submitted to the Journal."
NEJM editorial p. 1, Table 1, "Data on Myocardial Infarctions Omitting the Three Events": Rofecoxib | 2315 person-years of exposure | 17 myocardial infarctions | 4.25 relative risk; Naproxen | 2316 person-years of exposure | 4 myocardial infarctions.
NEJM editorial p. 1, Table 2, "Data on Myocardial Infarctions Including the Three Events": Rofecoxib | 2698 person-years of exposure | 20 myocardial infarctions | 5.00 relative risk; Naproxen | 2699 person-years of exposure | 4 myocardial infarctions.
